Comparative Pharmacology
Head-to-head clinical analysis: DESOWEN versus LOCORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOWEN versus LOCORTEN.
DESOWEN vs LOCORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desonide is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
Apply a thin film to affected skin areas twice daily. Maximum duration of continuous use is 2 weeks. Not for ophthalmic, oral, or intravaginal use.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
None Documented
None Documented
The terminal elimination half-life of desonide (active metabolite of desowen) is approximately 2-4 hours, but the pharmacodynamic half-life (skin blanching) extends to 12-24 hours due to cutaneous retention.
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Primarily renal (approximately 70-80% as metabolites, <5% unchanged) after topical application, with minimal biliary/fecal elimination (<10%).
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid